Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 2Completed 2Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Neoplasms 6Hematologic Neoplasms 4Breast Neoplasms 4Urinary Bladder Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Glioma 3Colorectal Neoplasms 3Prostatic Neoplasms 2Neoplasms by Site 2Motor Activity 2Head and Neck Neoplasms 2Glioblastoma 2Carcinoma, Transitional Cell 2Anxiety Disorders 2Anatomic Stage I Breast Cancer AJCC v8 2Uveal Melanoma 1Uterine Neoplasms 1Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Urinary Bladder Diseases 1Urethral Neoplasms 1Ureteral Neoplasms 1Stomatitis 1Stomach Neoplasms 1Smoking Cessation 1Small Cell Lung Carcinoma 1

Interventions

pembrolizumab 20atezolizumab 9Nivolumab 9Gemcitabine 9Docetaxel 5avelumab 4Mitomycin 4Carboplatin 4fludarabine 3epacadostat 3enfortumab vedotin 3Cyclophosphamide 3vofatamab 2valrubicin 2rucaparib 2pemigatinib 2durvalumab 2cabozantinib 2Standard of Care 2Sirolimus 2Radiation 2Pemetrexed 2Cisplatin 2Bevacizumab 2B701 protein, Human herpesvirus 6 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2trilaciclib 1temsirolimus 1spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Transitional Cell × Standard of Care × Clear all
NCT01310803 2017-10-05

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

Endo Pharmaceuticals

Phase 3 Terminated
1 enrolled 5 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT01353222 2017-05-25

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

Dendreon

Phase 2 Terminated
142 enrolled 13 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡